Related Experiment Video
Updated: Jul 4, 2025
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.2K
C-Type Natriuretic Peptide Analogs: Current and Future Therapeutic Applications
Despoina M Galetaki1, Andrew Dauber2,3
1Division of Endocrinology, Children's National Hospital, Washington, District of Columbia, USA, dgaletaki@childrensnational.org.
Hormone Research in Paediatrics
|February 8, 2024
Summary
Novel C-type natriuretic peptide (CNP) analogs offer new therapeutic avenues for children with short stature. Targeting the CNP/FGFR3 pathway shows promise for genetic growth conditions.
Area of Science:
- Pediatric Endocrinology
- Genetics
- Molecular Biology
Background:
- Short stature is a common pediatric referral, often with genetic causes.
- Current treatments like growth hormone and IGF-1 have limitations.
- Existing strategies focus on extending growth duration rather than direct stimulation.
Purpose of the Study:
- To review the function of C-type natriuretic peptide (CNP).
- To explore the potential of CNP analogs in treating various conditions causing short stature.
Main Methods:
- Literature review of CNP pathway and its role in growth.
- Analysis of genetic alterations affecting CNP signaling.
- Evaluation of therapeutic potential of CNP analogs.
Main Results:
- CNP plays a crucial role in skeletal growth.
- Dysregulation of the CNP/FGFR3 pathway is linked to genetic short stature.
- CNP analogs represent a novel therapeutic approach.
Conclusions:
- The CNP pathway is a key target for treating genetic short stature.
- CNP analogs demonstrate promising outcomes in preclinical and clinical studies.
- Targeting the CNP/FGFR3 pathway offers a new strategy for growth promotion.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:22Heart Failure Drugs: Diuretics
381
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
381
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
514
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
514
01:23Antihypertensive Drugs: Vasodilators
524
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
524
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
165
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165